Phase 1b, Open Label Study To Characterize The Distribution Of A Single Intravenous Dose Of [124i]-Iodobenzoyl (ib) Pf 06687234 With Concurrent Administration Of Non-radiolabeled Pf 06687234 As Assessed With Positron Emission Tomography And Computed Tomography (Pet-ct) Imaging In Moderate To Severe Ulcerative Colitis Subjects
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Apr 2018
At a glance
- Drugs F8 IL10 (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 09 Apr 2018 Planned End Date changed from 20 May 2019 to 29 May 2019.
- 09 Apr 2018 Planned primary completion date changed from 20 May 2019 to 29 May 2019.
- 09 Apr 2018 Planned initiation date changed from 28 Mar 2018 to 1 May 2018.